The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Stiefel, a GSK company, enters into an agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis

Wednesday, May 30, 2012

Stiefel, a GSK company, enters into an agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis15:04 EDT Wednesday, May 30, 2012VANCOUVER, May 30, 2012 /CNW/ - Stiefel, a GSK company, and Welichem Biotech Inc., have entered into  an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.  WBI-1001 is currently in Phase II clinical development for the treatment of psoriasis and atopic dermatitis.Welichem will receive an initial payment of CAD$35 million and is eligible to receive additional payments upon achievement of certain clinical development milestones and upon commercialization in certain countries following marketing approval from the corresponding regulatory agencies. The transaction is subject to approval by the shareholders of Welichem.Under terms of the agreement, Stiefel has also received a conditional right to acquire further exclusive rights to develop and commercialize WBI-1001 in China, Taiwan, Macao and Hong Kong, collectively, at a future date upon satisfaction of certain conditions and upon making an additional payment of CAD$15 million."Based on clinical results to date, we believe that WBI-1001 has the potential to be a first-line topical therapy for psoriasis and atopic dermatitis" said Dr. Liren Tang, President and CEO of Welichem, "As a leader in dermatology products, Stiefel has the clinical development and commercialization capabilities to bring this novel product to these patients around the world."About WBI-1001: WBI-1001 is a novel, non-steroidal, topical anti-inflammatory new chemical entity (NCE) agent that has demonstrated efficacy and safety in Ph1 and Ph2 clinical trials for the treatment of mild to moderate psoriasis and moderate to severe atopic dermatitis (AD) for up to 12 weeks as a single therapy.About Welichem Biotech Inc.Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancers.  For a more complete business and financial profile of the Company, interested parties are encouraged to visit the Company's website, TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.For further information: Liren Tang, President and Chief Executive Officer. Tel.: (604) 432-1703, Email: